ClinicalTrials.gg
CompletedNCT05046132Updated May 3, 2024Results posted

Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Participants

A Phase 4 interventional study of Setmelanotide and Moxifloxacin in Healthy, sponsored by Rhythm Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-03.

Sponsored by Rhythm Pharmaceuticals, Inc. · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
77
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This was a double-blind, randomized, placebo- and positive-controlled, parallel group, 3-arm study that assessed the potential for therapeutic and supratherapeutic concentrations of setmelanotide to affect the QTc corrected by the Fredericia method (QTcF) interval.

02

Conditions studied

  • Healthy

Keywords

  • Healthy Volunteers
03

In context

Lead sponsor

Rhythm Pharmaceuticals, Inc. is the lead sponsor of 29 studies on the registry; 2 are open to participants now.

Of its 19 completed or terminated interventional studies of FDA-regulated products, 15 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has (BMI) between 18.0 and 30.0 kilogram per meter square (kg/m\^2), inclusive.
  • Participant is in good health, as confirmed by no findings from medical history, physical examination, 12-lead (ECG), vital signs measurements, clinical laboratory evaluations, and liver function tests at Screening and Check-in.
  • Female participants of must be confirmed non-pregnant and agree to use .
  • Male participants with female partners of childbearing potential must agree to use contraception. Male participants must also not donate sperm during and for 90 days following their participation in the study.
  • Participant is a nonsmoker (for at least 3 months) with negative urinary cotinine test at Screening and agrees to abstain from alcohol, recreational drugs (including marijuana), and tobacco or nicotine-containing products for the duration of the study.
  • Participant is able to comprehend and is willing to sign an form and abide by the study restrictions.

Exclusion criteria

Exclusion Criteria:

  • Participant has sustained systolic blood pressure (SBP) >150 millimeters of mercury (mmHg) or \<90 mmHg or a diastolic blood pressure (DBP) >100 mmHg or \<60 mmHg in the supine position at Screening or Day 1 of each study period, respectively.
  • Participant has supine pulse rate of \<45 beats per minute (bpm) or >100 bpm.
  • Participant has abnormal screening indicating a second- or third-degree atrioventricular block, or one or more of the following: QRS>110 millisecond (msec) , >450 msec for males and >470 msec for females, PR interval >200 msec.
  • Participant has a history of risk factors for Torsades de Pointes (TdP), including unexplained syncope, diagnosis or family history of Brugada syndrome or long QT syndrome, heart failure, myocardial infarction, angina, or abnormal laboratory assessments including hypokalemia, hypercalcemia, or hypomagnesaemia.
  • (GFR) \<60 milliliter per minute (mL/min) at Screening.
  • Participant has significant dermatologic findings relating to melanoma or pre-melanoma skin lesions (excluding non-invasive basal or squamous cell lesion).
  • Participant has history or close family history (parents or siblings) of melanoma or participant history of ocular-cutaneous albinism.
  • Participant has significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder (as determined by the Investigator).
  • Participant has suicidal ideation of type 4 or 5 on the Columbia Suicide Severity Rating Scale (C-SSRS) at Screening, a history of a suicide attempt in the last 20 years, or any suicidal behavior in the last month.
  • Participant has participated in any clinical study with an drug/device within 30 days (or 5 half-lives) prior to the first day of dosing.
  • Participant was previously enrolled in a clinical study involving setmelanotide or any previous exposure to setmelanotide.
  • Participant has inability to comply with once daily dosing (QD) injection regimen.
  • Female participants who are breastfeeding or nursing.
  • Participant has cognitive impairment that, in the investigator's opinion, precludes participation to the study.
  • Participant is, in investigator's opinion, otherwise not suitable to participate in the study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
77 participants (actual)

Study arms

  • Experimental
    Group 1: Setmelanotide 2-7 mg + Placebo for Moxifloxacin

    Participants received titrated doses of 2-7 milligrams (mg) setmelanotide once daily by subcutaneous (SC) injection, starting with a dose of 2 mg from Days 1 to 7, 3 mg from Days 8 to 10, 5 mg from Days 11 to 13 and 7 mg from Days 14 to 16. Participants also received single oral dose of placebo matching moxifloxacin on Days 10 and 16.

    Drug: Setmelanotide · Drug: Oral Placebo

  • Active comparator
    Group 2: Placebo for Setmelanotide + Moxifloxacin 400 mg + Placebo for Moxifloxacin

    Participants received placebo matching setmelanotide once daily by SC injection from Days 1 to 16. Participants also received a single oral dose of 400 mg moxifloxacin on Day 10 and a single oral dose of placebo matching moxifloxacin on Day 16.

    Drug: Moxifloxacin · Drug: Oral Placebo · Drug: SC Placebo

  • Active comparator
    Group 3: Placebo for Setmelanotide + Placebo for Moxifloxacin + Moxifloxacin 400 mg

    Participants received placebo matching setmelanotide once daily by SC injection from Days 1 to 16. Participants also received a single oral dose of placebo matching moxifloxacin on Day 10 and a single oral dose of 400 mg moxifloxacin on Day 16.

    Drug: Moxifloxacin · Drug: Oral Placebo · Drug: SC Placebo

Interventions

  • Administered once daily via SC injection.

  • Moxifloxacin capsules via oral administration.

  • DrugOral Placebo

    Placebo capsules via oral administration.

  • DrugSC Placebo

    Placebo via SC injection.

06

What researchers measure

Primary outcomes

  1. Setmelanotide Concentration-related Placebo-corrected Change From Baseline (CHFB) in Fridericia's Correction (QTcF) at Day 10

    Continuous 12-lead digital electrocardiogram (ECG) recording was performed on Baseline and Day 10. ECG analysts were blinded to the treatment, timepoint and participant. QT interval was corrected for heart rate using QTcF. CHFB in QTcF was calculated at each timepoint.

    Time frame: Baseline and Day 10: Pre dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10,12, 16, 24 hours (hrs) postdose

  2. Setmelanotide Concentration-related Placebo-corrected CHFB in QTcF at Day 16

    Continuous 12-lead digital ECG recording was performed on Baseline and Day 16. ECG analysts were blinded to the treatment, timepoint and participant. QT interval was corrected for heart rate using QTcF. CHFB in QTcF was calculated at each timepoint.

    Time frame: Baseline and Day 16: Pre dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10,12, 16, 24 hrs postdose

Secondary outcomes

  1. Placebo-corrected CHFB in Heart Rate (HR) After Administration of SC Setmelanotide or Oral Moxifloxacin at Day 10

    The CHFB in HR was analyzed using an analysis of variance model (ANOVA) including treatment, time and their interaction as main factors and structuring the residual matrix in order to account for the repeated measurement pattern of the data. HR was considered as covariate. Placebo corrected values were reported in the inferential statistics.

    Time frame: Baseline and Day 10: Pre dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10,12, 16, 24 hours (hrs) postdose

  2. Placebo-corrected CHFB in HR After Administration of SC Setmelanotide or Oral Moxifloxacin at Day 16

    The CHFB in HR was analysed using an ANOVA including treatment, time and their interaction as main factors and structuring the residual matrix in order to account for the repeated measurement pattern of the data. HR was considered as covariate.

    Time frame: Baseline and Day 16: Pre dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10,12, 16, 24 hrs postdose

  3. Placebo-corrected CHFB in QTcF Intervals After Administration of SC Setmelanotide or Oral Moxifloxacin at Day 10

    The CHFB in QTcF was analyzed using an ANOVA including treatment, time and their interaction as main factors and structuring the residual matrix in order to account for the repeated measurement pattern of the data. HR was considered as covariate.

    Time frame: Baseline and Day 10: Pre dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10,12, 16, 24 hrs postdose

  4. Placebo-corrected CHFB in QTcF Intervals After Administration of SC Setmelanotide or Oral Moxifloxacin at Day 16

    The CHFB in QTcF was analysed using an ANOVA including treatment, time and their interaction as main factors and structuring the residual matrix in order to account for the repeated measurement pattern of the data. HR was considered as covariate.

    Time frame: Baseline and Day 16: Pre dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10,12, 16, 24 hrs postdose

  5. Placebo-corrected CHFB in PR Intervals After Administration of SC Setmelanotide or Oral Moxifloxacin at Day 10

    The CHFB in PR was analyzed using an ANOVA including treatment, time and their interaction as main factors and structuring the residual matrix in order to account for the repeated measurement pattern of the data. HR was considered as covariate.

    Time frame: Baseline and Day 10: Pre dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10,12, 16, 24 hrs postdose

  6. Placebo-corrected CHFB in PR Intervals After Administration of SC Setmelanotide or Oral Moxifloxacin at Day 16

    The CHFB in PR was analysed using an ANOVA including treatment, time and their interaction as main factors and structuring the residual matrix in order to account for the repeated measurement pattern of the data. HR was considered as covariate.

    Time frame: Baseline and Day 16: Pre dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10,12, 16, 24 hrs postdose

  7. Placebo-corrected CHFB in QRS Intervals After Administration of SC Setmelanotide or Oral Moxifloxacin at Day 10

    The CHFB in QRS was analysed using an ANOVA including treatment, time and their interaction as main factors and structuring the residual matrix in order to account for the repeated measurement pattern of the data. HR was considered as covariate.

    Time frame: Baseline and Day 10: Pre dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10,12, 16, 24 hrs postdose

  8. Placebo-corrected CHFB in QRS Intervals After Administration of SC Setmelanotide or Oral Moxifloxacin at Day 16

    The CHFB in QRS was analyzed using an ANOVA including treatment, time and their interaction as main factors and structuring the residual matrix in order to account for the repeated measurement pattern of the data. HR was considered as covariate.

    Time frame: Baseline and Day 16: Pre dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10,12, 16, 24 hrs postdose

  9. Number of Participants With at Least One Treatment-Emergent Abnormal Value in HR Intervals After Administration of SC Setmelanotide

    A treatment-emergent abnormality/finding was defined as any abnormality/finding not already reported on any of the ECGs collected before the administration. Abnormal findings included: HR (\<40 beats/min, HR\>120 beats/min and Relative CHFB \>25%) Relative CHFB = 100\*(Value-Baseline)/Baseline

    Time frame: Day 10 (for setmelanotide 3 mg) and Day 16 (for setmelanotide 7mg)

  10. Number of Participants With at Least One Treatment-Emergent Abnormal Value in PR Intervals After Administration of SC Setmelanotide

    A treatment-emergent abnormality/finding was defined as any abnormality/finding not already reported on any of the ECGs collected before the administration. Abnormal findings included: PR (\>220 msec, Relative CHFB \>25%); Relative CHFB = 100\*(Value-Baseline)/Baseline

    Time frame: Day 10 (for setmelanotide 3 mg) and Day 16 (for setmelanotide 7mg)

  11. Number of Participants With at Least One Treatment-Emergent Abnormal Value in QRS Intervals After Administration of SC Setmelanotide

    A treatment-emergent abnormality/finding was defined as any abnormality/finding not already reported on any of the ECGs collected before the administration. Abnormal findings included: QRS ( \>120 msec, Relative CHFB \>25%); Relative CHFB = 100\*(Value-Baseline)/Baseline

    Time frame: Day 10 (for setmelanotide 3 mg) and Day 16 (for setmelanotide 7mg)

  12. Number of Participants With at Least One Treatment-Emergent Abnormal Value in QTcF Intervals After Administration of SC Setmelanotide

    A treatment-emergent abnormality/finding was defined as any abnormality/finding not already reported on any of the ECGs collected before the administration. Abnormal findings included: QTcF (450\<QTc\<=480 msec, 480\<QTc\<=500 msec, QTc\>500 msec, 30\<CHFB in QTc\<=60 msec, CHFB in \>60 msec)

    Time frame: Day 10 (for setmelanotide 3 mg) and Day 16 (for setmelanotide 7mg)

  13. Number of Participants With at Least One Treatment-Emergent Abnormal Finding in T-wave Morphology and U-wave Presence After Administration of SC Setmelanotide

    A treatment-emergent abnormality/finding will be defined as any abnormality/finding not already reported on any of the ECGs collected before the administration. Abnormal findings included : QTcF Increase From Baseline, \> 30 msec And \< 60 msec

    Time frame: Day 10 (for setmelanotide 3 mg) and Day 16 (for setmelanotide 7mg)

  14. Moxifloxacin Concentration-related CHFB in QTcF at Day 10

    Continuous 12-lead digital ECG recording was performed on Baseline and Day 10. ECG analysts were blinded to the treatment, timepoint and participant. CHFB in QTcF was calculated at each timepoint.

    Time frame: Baseline and Day 10: Pre dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10,12, 16, 24 hrs postdose

  15. Moxifloxacin Concentration-related CHFB in QTcF at Day 16

    Continuous 12-lead digital ECG recording was performed on Baseline and Day 16. ECG analysts were blinded to the treatment, timepoint and participant. CHFB in QTcF was calculated at each timepoint.

    Time frame: Baseline and Day 16: Pre dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10,12, 16, 24 hrs postdose

07

Results

Posted May 3, 2024

Participant flow

77 healthy participants aged 18 to 50 years, inclusive, were enrolled in the United States.

Participant flow — Overall Study
MilestoneGroup 1: Setmelanotide 2-7 mg + Placebo for MoxifloxacinGroup 2: Placebo for Setmelanotide + Moxifloxacin 400 mg + Placebo for MoxifloxacinGroup 3: Placebo for Setmelanotide + Placebo for Moxifloxacin + Moxifloxacin 400 mg
Started282425
Received 2 mg setmelanotide2800
Received 3 mg setmelanotide2400
Received 5 mg setmelanotide2300
Received 7 mg setmelanotide2100
Completed212325
Not completed710
Withdrew: Adverse event400
Withdrew: Withdrawal by subject300
Withdrew: Positive covid19 result.010

Outcome measures

PrimarySetmelanotide Concentration-related Placebo-corrected Change From Baseline (CHFB) in Fridericia's Correction (QTcF) at Day 10

Continuous 12-lead digital electrocardiogram (ECG) recording was performed on Baseline and Day 10. ECG analysts were blinded to the treatment, timepoint and participant. QT interval was corrected for heart rate using QTcF. CHFB in QTcF was calculated at each timepoint.

Time frame:
Baseline and Day 10: Pre dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10,12, 16, 24 hours (hrs) postdose
Reported as:
Mean · milliseconds (msec)
Setmelanotide Concentration-related Placebo-corrected Change From Baseline (CHFB) in Fridericia's Correction (QTcF) at Day 10
milliseconds (msec)Group 1: Setmelanotide 3 mgGroup 3: Placebo
Predose1.9 ± 7.82-1.5 ± 5.25
0.5 hr Post dose-3.6 ± 9.83-3.5 ± 8.16
1 hr Post dose-2.9 ± 12.69-3.5 ± 5.87
1.5 hr Post dose-3.0 ± 9.53-3.2 ± 7.44
2 hr Post dose-1.0 ± 11.26-3.4 ± 5.70
2.5 hr Post dose1.2 ± 11.22-2.0 ± 8.92
3 hr Post dose2.1 ± 10.06-2.6 ± 6.75
4 hr Post dose2.0 ± 9.76-2.4 ± 8.09
5 hr Post dose2.4 ± 9.380.2 ± 8.99
6 hr Post dose-0.4 ± 9.71-1.8 ± 6.88
7 hr Post dose1.0 ± 8.02-1.3 ± 7.36
8 hr Post dose2.6 ± 9.11-0.3 ± 7.93
9 hr Post dose4.1 ± 7.84-2.0 ± 6.58
10 hr Post dose5.0 ± 8.14-0.9 ± 9.96
12 hr Post dose1.9 ± 9.253.4 ± 8.65
16 hr Post dose1.7 ± 7.46-1.0 ± 7.64
24 hr Post dose-0.7 ± 13.321.6 ± 8.28
Statistical analysis
  • Group 1: Setmelanotide 3 mg vs Group 3: Placebo · Mean of placebo-corrected chfb: 3.70 · 90% CI 1.23 to 6.17
PrimarySetmelanotide Concentration-related Placebo-corrected CHFB in QTcF at Day 16

Continuous 12-lead digital ECG recording was performed on Baseline and Day 16. ECG analysts were blinded to the treatment, timepoint and participant. QT interval was corrected for heart rate using QTcF. CHFB in QTcF was calculated at each timepoint.

Time frame:
Baseline and Day 16: Pre dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10,12, 16, 24 hrs postdose
Reported as:
Mean · msec
Setmelanotide Concentration-related Placebo-corrected CHFB in QTcF at Day 16
msecGroup 1: Setmelanotide 7 mgGroup 2: Placebo
Predose4.5 ± 6.49-2.3 ± 8.24
0.5 hr Post dose1.0 ± 8.83-5.2 ± 6.97
1 hr Post dose1.6 ± 9.18-4.3 ± 8.20
1.5 hr Post dose0.3 ± 10.42-2.9 ± 8.64
2 hr Post dose2.2 ± 10.94-2.0 ± 8.96
2.5 hr Post dose2.7 ± 11.61-2.5 ± 9.09
3 hr Post dose4.3 ± 11.34-2.0 ± 8.07
4 hr Post dose3.6 ± 9.88-2.5 ± 6.37
5 hr Post dose4.7 ± 9.41-0.5 ± 6.42
6 hr Post dose2.8 ± 9.64-2.4 ± 7.28
7 hr Post dose1.5 ± 11.14-2.0 ± 6.31
8 hr Post dose2.8 ± 10.02-2.6 ± 8.27
9 hr Post dose6.1 ± 8.72-1.2 ± 7.00
10 hr Post dose6.5 ± 6.64-2.5 ± 7.14
12 hr Post dose5.8 ± 7.96-0.4 ± 5.99
16 hr Post dose1.4 ± 7.77-2.6 ± 9.30
24 hr Post dose1.0 ± 11.26-5.6 ± 9.67
Statistical analysis
  • Group 1: Setmelanotide 7 mg vs Group 2: Placebo · Mean of placebo-corrected chfb: 4.67 · 90% CI 1.70 to 7.64
SecondaryPlacebo-corrected CHFB in Heart Rate (HR) After Administration of SC Setmelanotide or Oral Moxifloxacin at Day 10

The CHFB in HR was analyzed using an analysis of variance model (ANOVA) including treatment, time and their interaction as main factors and structuring the residual matrix in order to account for the repeated measurement pattern of the data. HR was considered as covariate. Placebo corrected values were reported in the inferential statistics.

Time frame:
Baseline and Day 10: Pre dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10,12, 16, 24 hours (hrs) postdose
Reported as:
Mean · beats per minute (bpm)
Placebo-corrected CHFB in Heart Rate (HR) After Administration of SC Setmelanotide or Oral Moxifloxacin at Day 10
beats per minute (bpm)Group 1: Setmelanotide 3 mgGroup 2: Moxifloxacin 400 mg
Pre dose2.3 ± 9.65-0.3 ± 7.31
0.5 hr Post dose-2.0 ± 9.580.9 ± 6.39
1 hr Post dose-2.7 ± 11.671.3 ± 5.79
1.5 hr Post dose-0.2 ± 13.132.0 ± 5.51
2 hr Post dose-2.1 ± 10.940.0 ± 6.77
2.5 hr Post dose-1.8 ± 9.311.7 ± 6.33
3 hr Post dose0.2 ± 10.70-0.4 ± 8.47
4 hr Post dose-1.2 ± 7.91-0.6 ± 6.26
5 hr Post dose0.6 ± 7.513.1 ± 7.36
6 hr Post dose-1.3 ± 7.663.6 ± 5.97
7 hr Post dose-2.9 ± 6.450.9 ± 4.74
8 hr Post dose-2.2 ± 5.932.4 ± 7.04
9 hr Post dose-1.3 ± 6.341.3 ± 6.27
10 hr Post dose-0.8 ± 5.820.9 ± 5.33
12 hr Post dose-2.8 ± 7.493.3 ± 6.03
16 hr Post dose1.7 ± 6.931.9 ± 7.00
24 hr Post dose2.1 ± 6.041.3 ± 5.37
Statistical analysis
  • Group 1: Setmelanotide 3 mg · Ls mean: 2.5 · 90% CI -0.6 to 5.6
  • Group 1: Setmelanotide 3 mg · Ls mean: 0.1 · 90% CI -3.0 to 3.1
  • Group 1: Setmelanotide 3 mg · Ls mean: 0.1 · 90% CI -2.8 to 3.0
  • Group 1: Setmelanotide 3 mg · Ls mean: 1.6 · 90% CI -1.8 to 5.1
  • Group 1: Setmelanotide 3 mg · Ls mean: 0.7 · 90% CI -2.8 to 4.1
  • Group 1: Setmelanotide 3 mg · Ls mean: 0.2 · 90% CI -2.9 to 3.4
  • Group 1: Setmelanotide 3 mg · Ls mean: 2.2 · 90% CI -1.4 to 5.7
  • Group 1: Setmelanotide 3 mg · Ls mean: -0.1 · 90% CI -2.9 to 2.7
  • Group 1: Setmelanotide 3 mg · Ls mean: -0.2 · 90% CI -3.1 to 2.7
  • Group 1: Setmelanotide 3 mg · Ls mean: -0.8 · 90% CI -3.8 to 2.3
  • Group 1: Setmelanotide 3 mg · Ls mean: -2.8 · 90% CI -5.5 to -0.1
  • Group 1: Setmelanotide 3 mg · Ls mean: -1.6 · 90% CI -4.5 to 1.3
  • Group 1: Setmelanotide 3 mg · Ls mean: 0.3 · 90% CI -2.5 to 3.0
  • Group 1: Setmelanotide 3 mg · Ls mean: 0.2 · 90% CI -2.3 to 2.7
  • Group 1: Setmelanotide 3 mg · Ls mean: -3.0 · 90% CI -5.9 to -0.1
  • Group 1: Setmelanotide 3 mg · Ls mean: -2.0 · 90% CI -5.1 to 1.0
  • Group 1: Setmelanotide 3 mg · Ls mean: 1.1 · 90% CI -1.6 to 3.8
  • Group 2: Moxifloxacin 400 mg · Ls mean: 1.4 · 90% CI -1.7 to 4.5
  • Group 2: Moxifloxacin 400 mg · Ls mean: 1.7 · 90% CI -1.4 to 4.7
  • Group 2: Moxifloxacin 400 mg · Ls mean: 1.9 · 90% CI -1.0 to 4.8
  • Group 2: Moxifloxacin 400 mg · Ls mean: 2.6 · 90% CI -0.9 to 6.0
  • Group 2: Moxifloxacin 400 mg · Ls mean: 1.3 · 90% CI -2.1 to 4.8
  • Group 2: Moxifloxacin 400 mg · Ls mean: 1.7 · 90% CI -1.4 to 4.9
  • Group 2: Moxifloxacin 400 mg · Ls mean: 1.6 · 90% CI -1.9 to 5.1
  • Group 2: Moxifloxacin 400 mg · Ls mean: 1.4 · 90% CI -1.4 to 4.2
  • Group 2: Moxifloxacin 400 mg · Ls mean: 2.7 · 90% CI -0.2 to 5.7
  • Group 2: Moxifloxacin 400 mg · Ls mean: 4.4 · 90% CI 1.4 to 7.5
  • Group 2: Moxifloxacin 400 mg · Ls mean: 2.8 · 90% CI 0.1 to 5.5
  • Group 2: Moxifloxacin 400 mg · Ls mean: 4.1 · 90% CI 1.2 to 7.0
  • Group 2: Moxifloxacin 400 mg · Ls mean: 3.6 · 90% CI 0.8 to 6.3
  • Group 2: Moxifloxacin 400 mg · Ls mean: 3.3 · 90% CI 0.8 to 5.8
  • Group 2: Moxifloxacin 400 mg · Ls mean: 2.6 · 90% CI -0.3 to 5.5
  • Group 2: Moxifloxacin 400 mg · Ls mean: 0.3 · 90% CI -2.7 to 3.4
  • Group 2: Moxifloxacin 400 mg · Ls mean: 1.7 · 90% CI -1.0 to 4.4
SecondaryPlacebo-corrected CHFB in HR After Administration of SC Setmelanotide or Oral Moxifloxacin at Day 16

The CHFB in HR was analysed using an ANOVA including treatment, time and their interaction as main factors and structuring the residual matrix in order to account for the repeated measurement pattern of the data. HR was considered as covariate.

Time frame:
Baseline and Day 16: Pre dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10,12, 16, 24 hrs postdose
Reported as:
Mean · bpm
Placebo-corrected CHFB in HR After Administration of SC Setmelanotide or Oral Moxifloxacin at Day 16
bpmGroup 1: Setmelanotide 7 mgGroup 3: Moxifloxacin 400 mg
Pre dose3.4 ± 7.41-0.3 ± 4.95
0.5 hr Post dose-1.7 ± 9.57-0.1 ± 6.35
1 hr Post dose-2.2 ± 10.610.1 ± 5.96
1.5 hr Post dose-1.5 ± 10.351.5 ± 5.78
2 hr Post dose-3.0 ± 7.190.5 ± 5.14
2.5 hr Post dose-0.8 ± 7.240.4 ± 6.49
3 hr Post dose-0.2 ± 7.112.1 ± 5.44
4 hr Post dose1.5 ± 6.902.0 ± 5.18
5 hr Post dose3.5 ± 7.843.4 ± 5.76
6 hr Post dose3.9 ± 9.210.7 ± 5.66
7 hr Post dose1.2 ± 6.713.3 ± 7.68
8 hr Post dose0.8 ± 7.132.8 ± 4.71
9 hr Post dose1.5 ± 7.301.6 ± 6.59
10 hr Post dose2.1 ± 7.822.8 ± 5.16
12 hr Post dose0.6 ± 8.003.0 ± 3.86
16 hr Post dose3.0 ± 6.983.3 ± 4.75
24 hr Post dose6.2 ± 7.410.4 ± 6.39
Statistical analysis
  • Group 1: Setmelanotide 7 mg · Ls mean: 0.3 · 90% CI -2.8 to 3.4
  • Group 1: Setmelanotide 7 mg · Ls mean: -2.1 · 90% CI -5.3 to 1.0
  • Group 1: Setmelanotide 7 mg · Ls mean: -1.6 · 90% CI -4.7 to 1.4
  • Group 1: Setmelanotide 7 mg · Ls mean: -2.2 · 90% CI -5.3 to 1.0
  • Group 1: Setmelanotide 7 mg · Ls mean: -3.3 · 90% CI -6.3 to -0.3
  • Group 1: Setmelanotide 7 mg · Ls mean: -1.2 · 90% CI -4.1 to 1.7
  • Group 1: Setmelanotide 7 mg · Ls mean: -1.3 · 90% CI -4.2 to 1.7
  • Group 1: Setmelanotide 7 mg · Ls mean: -0.6 · 90% CI -3.6 to 2.5
  • Group 1: Setmelanotide 7 mg · Ls mean: -1.0 · 95% CI -4.1 to 2.1
  • Group 1: Setmelanotide 7 mg · Ls mean: 0.4 · 90% CI -2.7 to 3.5
  • Group 1: Setmelanotide 7 mg · Ls mean: -2.5 · 90% CI -5.5 to 0.5
  • Group 1: Setmelanotide 7 mg · Ls mean: -2.2 · 90% CI -5.2 to 0.8
  • Group 1: Setmelanotide 7 mg · Ls mean: -0.9 · 90% CI -4.3 to 2.6
  • Group 1: Setmelanotide 7 mg · Ls mean: -0.2 · 90% CI -3.6 to 3.2
  • Group 1: Setmelanotide 7 mg · Ls mean: -2.2 · 90% CI -5.5 to 1.0
  • Group 1: Setmelanotide 7 mg · Ls mean: -1.9 · 90% CI -5.4 to 1.7
  • Group 1: Setmelanotide 7 mg · Ls mean: 2.6 · 90% CI -1.2 to 6.3
  • Group 3: Moxifloxacin 400 mg · Ls mean: -2.1 · 90% CI -5.1 to 0.8
  • Group 3: Moxifloxacin 400 mg · Ls mean: -0.1 · 90% CI -3.1 to 3.0
  • Group 3: Moxifloxacin 400 mg · Ls mean: -0.1 · 90% CI -3.0 to 2.9
  • Group 3: Moxifloxacin 400 mg · Ls mean: -0.1 · 90% CI -3.1 to 3.0
  • Group 3: Moxifloxacin 400 mg · Ls mean: -0.9 · 90% CI -3.8 to 2.0
  • Group 3: Moxifloxacin 400 mg · Ls mean: 0.2 · 90% CI -2.5 to 3.0
  • Group 3: Moxifloxacin 400 mg · Ls mean: 0.9 · 90% CI -1.9 to 3.7
  • Group 3: Moxifloxacin 400 mg · Ls mean: 0.7 · 90% CI -2.2 to 3.7
  • Group 3: Moxifloxacin 400 mg · Ls mean: 0.1 · 90% CI -2.8 to 3.1
  • Group 3: Moxifloxacin 400 mg · Ls mean: -0.9 · 90% CI -3.9 to 2.0
  • Group 3: Moxifloxacin 400 mg · Ls mean: -0.2 · 90% CI -3.1 to 2.7
  • Group 3: Moxifloxacin 400 mg · Ls mean: 0.2 · 90% CI -2.7 to 3.1
  • Group 3: Moxifloxacin 400 mg · Ls mean: 0.7 · 90% CI -2.7 to 4.0
  • Group 3: Moxifloxacin 400 mg · Ls mean: 0.9 · 90% CI -2.3 to 4.1
  • Group 3: Moxifloxacin 400 mg · Ls mean: -0.4 · 90% CI -3.5 to 2.8
  • Group 3: Moxifloxacin 400 mg · Ls mean: -0.4 · 90% CI -3.8 to 3.0
  • Group 3: Moxifloxacin 400 mg · Ls mean: -1.6 · 90% CI -5.1 to 2.0
SecondaryPlacebo-corrected CHFB in QTcF Intervals After Administration of SC Setmelanotide or Oral Moxifloxacin at Day 10

The CHFB in QTcF was analyzed using an ANOVA including treatment, time and their interaction as main factors and structuring the residual matrix in order to account for the repeated measurement pattern of the data. HR was considered as covariate.

Time frame:
Baseline and Day 10: Pre dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10,12, 16, 24 hrs postdose
Reported as:
Mean · msec
Placebo-corrected CHFB in QTcF Intervals After Administration of SC Setmelanotide or Oral Moxifloxacin at Day 10
msecGroup 1: Setmelanotide 3 mgGroup 2: Moxifloxacin 400 mg
Pre dose1.9 ± 7.821.5 ± 7.76
0.5 hr Post dose-3.6 ± 9.83-5.3 ± 8.75
1 hr Post dose-2.9 ± 12.69-3.7 ± 9.39
1.5 hr Post dose-3.0 ± 9.530.9 ± 8.56
2 hr Post dose-1.0 ± 11.262.0 ± 8.74
2.5 hr Post dose1.2 ± 11.224.9 ± 8.75
3 hr Post dose2.1 ± 10.064.9 ± 7.39
4 hr Post dose2.0 ± 9.766.3 ± 8.63
5 hr Post dose2.4 ± 9.388.1 ± 8.42
6 hr Post dose-0.4 ± 9.716.0 ± 6.61
7 hr Post dose1.0 ± 8.025.1 ± 8.39
8 hr Post dose2.6 ± 9.114.4 ± 8.18
9 hr Post dose4.1 ± 7.845.0 ± 10.47
10 hr Post dose5.0 ± 8.146.2 ± 6.85
12 hr Post dose1.9 ± 9.258.7 ± 4.84
16 hr Post dose1.7 ± 7.465.9 ± 8.09
24 hr Post dose-0.7 ± 13.326.6 ± 8.00
Statistical analysis
  • Group 1: Setmelanotide 3 mg · Ls mean: 3.5 · 90% CI 0.1 to 6.8
  • Group 1: Setmelanotide 3 mg · Ls mean: 0.8 · 90% CI -3.0 to 4.6
  • Group 1: Setmelanotide 3 mg · Ls mean: -0.1 · 90% CI -4.1 to 3.9
  • Group 1: Setmelanotide 3 mg · Ls mean: 0.9 · 90% CI -2.7 to 4.4
  • Group 1: Setmelanotide 3 mg · Ls mean: 3.0 · 90% CI -0.6 to 6.6
  • Group 1: Setmelanotide 3 mg · Ls mean: 3.5 · 90% CI -0.3 to 7.4
  • Group 1: Setmelanotide 3 mg · Ls mean: 4.6 · 90% CI 1.2 to 8.1
  • Group 1: Setmelanotide 3 mg · Ls mean: 5.2 · 90% CI 1.5 to 8.9
  • Group 1: Setmelanotide 3 mg · Ls mean: 2.0 · 90% CI -1.7 to 5.8
  • Group 1: Setmelanotide 3 mg · Ls mean: 1.7 · 90% CI -1.6 to 5.1
  • Group 1: Setmelanotide 3 mg · Ls mean: 2.3 · 90% CI -1.1 to 5.7
  • Group 1: Setmelanotide 3 mg · Ls mean: 2.4 · 90% CI -1.4 to 6.2
  • Group 1: Setmelanotide 3 mg · Ls mean: 4.4 · 90% CI 0.9 to 7.8
  • Group 1: Setmelanotide 3 mg · Ls mean: 3.8 · 90% CI 0.3 to 7.4
  • Group 1: Setmelanotide 3 mg · Ls mean: -0.8 · 90% CI -4.2 to 2.7
  • Group 1: Setmelanotide 3 mg · Ls mean: 3.6 · 90% CI 0.1 to 7.0
  • Group 1: Setmelanotide 3 mg · Ls mean: -1.5 · 90% CI -5.7 to 2.8
  • Group 2: Moxifloxacin 400 mg · Ls mean: 2.3 · 90% CI -1.0 to 5.6
  • Group 2: Moxifloxacin 400 mg · Ls mean: -1.6 · 90% CI -5.4 to 2.2
  • Group 2: Moxifloxacin 400 mg · Ls mean: 0.3 · 90% CI -3.8 to 4.3
  • Group 2: Moxifloxacin 400 mg · Ls mean: 4.0 · 90% CI 0.4 to 7.6
  • Group 2: Moxifloxacin 400 mg · Ls mean: 6.3 · 90% CI 2.7 to 10.0
  • Group 2: Moxifloxacin 400 mg · Ls mean: 6.4 · 90% CI 2.6 to 10.2
  • Group 2: Moxifloxacin 400 mg · Ls mean: 8.5 · 90% CI 5.0 to 12.0
  • Group 2: Moxifloxacin 400 mg · Ls mean: 10.1 · 90% CI 6.4 to 13.8
  • Group 2: Moxifloxacin 400 mg · Ls mean: 7.8 · 90% CI 4.1 to 11.6
  • Group 2: Moxifloxacin 400 mg · Ls mean: 7.8 · 90% CI 4.4 to 11.2
  • Group 2: Moxifloxacin 400 mg · Ls mean: 6.8 · 90% CI 3.4 to 10.2
  • Group 2: Moxifloxacin 400 mg · Ls mean: 4.5 · 90% CI 0.6 to 8.3
  • Group 2: Moxifloxacin 400 mg · Ls mean: 6.5 · 90% CI 3.1 to 10.0
  • Group 2: Moxifloxacin 400 mg · Ls mean: 6.6 · 90% CI 3.0 to 10.1
  • Group 2: Moxifloxacin 400 mg · Ls mean: 5.3 · 90% CI 1.8 to 8.8
  • Group 2: Moxifloxacin 400 mg · Ls mean: 7.2 · 90% CI 3.7 to 10.6
  • Group 2: Moxifloxacin 400 mg · Ls mean: 3.3 · 90% CI -1.0 to 7.5
SecondaryPlacebo-corrected CHFB in QTcF Intervals After Administration of SC Setmelanotide or Oral Moxifloxacin at Day 16

The CHFB in QTcF was analysed using an ANOVA including treatment, time and their interaction as main factors and structuring the residual matrix in order to account for the repeated measurement pattern of the data. HR was considered as covariate.

Time frame:
Baseline and Day 16: Pre dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10,12, 16, 24 hrs postdose
Reported as:
Mean · msec
Placebo-corrected CHFB in QTcF Intervals After Administration of SC Setmelanotide or Oral Moxifloxacin at Day 16
msecGroup 1: Setmelanotide 7 mgGroup 3: Moxifloxacin 400 mg
Pre dose4.5 ± 6.49-0.8 ± 8.30
0.5 hr Post dose1.0 ± 8.83-1.8 ± 5.93
1 hr Post dose1.6 ± 9.18-1.9 ± 7.49
1.5 hr Post dose0.3 ± 10.423.0 ± 7.05
2 hr Post dose2.2 ± 10.944.2 ± 7.53
2.5 hr Post dose2.7 ± 11.617.6 ± 8.45
3 hr Post dose4.3 ± 11.348.1 ± 8.19
4 hr Post dose3.6 ± 9.888.8 ± 6.37
5 hr Post dose4.7 ± 9.417.5 ± 8.97
6 hr Post dose2.8 ± 9.648.5 ± 6.18
7 hr Post dose1.5 ± 11.149.1 ± 7.29
8 hr Post dose2.8 ± 10.028.0 ± 5.73
9 hr Post dose6.1 ± 8.727.0 ± 7.33
10 hr Post dose6.5 ± 6.647.0 ± 9.93
12 hr Post dose5.8 ± 7.9610.8 ± 9.14
16 hr Post dose1.4 ± 7.776.6 ± 8.51
24 hr Post dose1.0 ± 11.264.4 ± 10.57
Statistical analysis
  • Group 1: Setmelanotide 7 mg · Ls mean: 7.8 · 90% CI 3.7 to 11.8
  • Group 1: Setmelanotide 7 mg · Ls mean: 6.5 · 90% CI 3.3 to 9.8
  • Group 1: Setmelanotide 7 mg · Ls mean: 4.6 · 90% CI 0.6 to 8.6
  • Group 1: Setmelanotide 7 mg · Ls mean: 4.6 · 90% CI 0.6 to 8.6
  • Group 1: Setmelanotide 7 mg · Ls mean: 3.8 · 90% CI -0.4 to 8.0
  • Group 1: Setmelanotide 7 mg · Ls mean: 6.1 · 90% CI 1.8 to 10.4
  • Group 1: Setmelanotide 7 mg · Ls mean: 5.7 · 90% CI 1.7 to 9.8
  • Group 1: Setmelanotide 7 mg · Ls mean: 6.2 · 90% CI 2.5 to 9.8
  • Group 1: Setmelanotide 7 mg · Ls mean: 5.7 · 90% CI 1.6 to 9.8
  • Group 1: Setmelanotide 7 mg · Ls mean: 4.8 · 90% CI 1.1 to 8.4
  • Group 1: Setmelanotide 7 mg · Ls mean: 3.0 · 90% CI -0.9 to 7.0
  • Group 1: Setmelanotide 7 mg · Ls mean: 5.0 · 90% CI 1.3 to 8.8
  • Group 1: Setmelanotide 7 mg · Ls mean: 6.5 · 90% CI 2.5 to 10.6
  • Group 1: Setmelanotide 7 mg · Ls mean: 8.6 · 90% CI 4.8 to 12.3
  • Group 1: Setmelanotide 7 mg · Ls mean: 7.9 · 90% CI 4.4 to 11.4
  • Group 1: Setmelanotide 7 mg · Ls mean: 4.9 · 90% CI 0.9 to 8.9
  • Group 1: Setmelanotide 7 mg · Ls mean: 7.8 · 90% CI 3.6 to 12.0
  • Group 3: Moxifloxacin 400 mg · Ls mean: 2.1 · 90% CI -1.8 to 6.0
  • Group 3: Moxifloxacin 400 mg · Ls mean: 3.1 · 90% CI -0.0 to 6.2
  • Group 3: Moxifloxacin 400 mg · Ls mean: 1.9 · 90% CI -1.9 to 5.7
  • Group 3: Moxifloxacin 400 mg · Ls mean: 6.5 · 90% CI 2.6 to 10.4
  • Group 3: Moxifloxacin 400 mg · Ls mean: 5.3 · 90% CI 1.3 to 9.3
  • Group 3: Moxifloxacin 400 mg · Ls mean: 11.1 · 90% CI 7.0 to 15.1
  • Group 3: Moxifloxacin 400 mg · Ls mean: 9.8 · 90% CI 5.9 to 13.6
  • Group 3: Moxifloxacin 400 mg · Ls mean: 10.7 · 90% CI 7.2 to 14.2
  • Group 3: Moxifloxacin 400 mg · Ls mean: 8.8 · 90% CI 4.9 to 12.7
  • Group 3: Moxifloxacin 400 mg · Ls mean: 11.0 · 90% CI 7.5 to 14.5
  • Group 3: Moxifloxacin 400 mg · Ls mean: 10.8 · 90% CI 7.1 to 14.6
  • Group 3: Moxifloxacin 400 mg · Ls mean: 11.3 · 90% CI 7.6 to 14.9
  • Group 3: Moxifloxacin 400 mg · Ls mean: 9.8 · 90% CI 5.9 to 13.7
  • Group 3: Moxifloxacin 400 mg · Ls mean: 10.5 · 90% CI 6.9 to 14.1
  • Group 3: Moxifloxacin 400 mg · Ls mean: 11.8 · 90% CI 8.4 to 15.2
  • Group 3: Moxifloxacin 400 mg · Ls mean: 9.4 · 90% CI 5.6 to 13.3
  • Group 3: Moxifloxacin 400 mg · Ls mean: 10.8 · 90% CI 6.8 to 14.9
SecondaryPlacebo-corrected CHFB in PR Intervals After Administration of SC Setmelanotide or Oral Moxifloxacin at Day 10

The CHFB in PR was analyzed using an ANOVA including treatment, time and their interaction as main factors and structuring the residual matrix in order to account for the repeated measurement pattern of the data. HR was considered as covariate.

Time frame:
Baseline and Day 10: Pre dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10,12, 16, 24 hrs postdose
Reported as:
Mean · msec
Placebo-corrected CHFB in PR Intervals After Administration of SC Setmelanotide or Oral Moxifloxacin at Day 10
msecGroup 1: Setmelanotide 3 mgGroup 2: Moxifloxacin 400 mg
Pre dose-2.4 ± 6.123.1 ± 5.18
0.5 hr Post dose-3.8 ± 8.933.4 ± 8.29
1 hr Post dose-1.0 ± 6.223.5 ± 7.33
1.5 hr Post dose-1.0 ± 6.243.7 ± 7.04
2 hr Post dose-1.0 ± 6.983.3 ± 7.44
2.5 hr Post dose-3.1 ± 4.921.5 ± 6.53
3 hr Post dose-3.9 ± 7.812.6 ± 6.76
4 hr Post dose-1.2 ± 5.781.6 ± 8.41
5 hr Post dose-1.0 ± 6.610.5 ± 5.46
6 hr Post dose-1.7 ± 5.87-0.2 ± 6.62
7 hr Post dose-2.5 ± 4.880.3 ± 5.06
8 hr Post dose-1.9 ± 7.060.3 ± 7.37
9 hr Post dose-2.3 ± 6.030.5 ± 4.49
10 hr Post dose-1.2 ± 7.06-0.8 ± 6.30
12 hr Post dose-3.9 ± 7.83-2.1 ± 6.05
16 hr Post dose-3.0 ± 7.02-0.0 ± 7.24
24 hr Post dose-6.6 ± 8.391.2 ± 5.65
Statistical analysis
  • Group 1: Setmelanotide 3 mg · Ls mean: -5.3 · 90% CI -8.4 to -2.2
  • Group 2: Moxifloxacin 400 mg · Ls mean: -2.7 · 90% CI -5.9 to 0.5
  • Group 1: Setmelanotide 3 mg · Ls mean: -3.2 · 90% CI -5.7 to -0.7
  • Group 1: Setmelanotide 3 mg · Ls mean: -0.9 · 90% CI -3.7 to 1.9
  • Group 1: Setmelanotide 3 mg · Ls mean: -2.9 · 90% CI -5.7 to -0.2
  • Group 1: Setmelanotide 3 mg · Ls mean: -4.0 · 90% CI -6.5 to -1.5
  • Group 1: Setmelanotide 3 mg · Ls mean: -4.2 · 90% CI -7.1 to -1.3
  • Group 1: Setmelanotide 3 mg · Ls mean: -4.1 · 90% CI -7.4 to -0.8
  • Group 1: Setmelanotide 3 mg · Ls mean: -0.8 · 90% CI -3.7 to 2.1
  • Group 1: Setmelanotide 3 mg · Ls mean: -3.3 · 90% CI -6.3 to -0.4
  • Group 1: Setmelanotide 3 mg · Ls mean: -3.3 · 90% CI -6.0 to -0.5
  • Group 1: Setmelanotide 3 mg · Ls mean: -1.6 · 90% CI -4.7 to 1.5
  • Group 1: Setmelanotide 3 mg · Ls mean: -4.0 · 90% CI -6.9 to -1.2
  • Group 1: Setmelanotide 3 mg · Ls mean: -4.3 · 90% CI -7.6 to -1.0
  • Group 1: Setmelanotide 3 mg · Ls mean: -5.4 · 90% CI -8.7 to -2.1
  • Group 1: Setmelanotide 3 mg · Ls mean: -4.1 · 90% CI -7.4 to -0.8
  • Group 1: Setmelanotide 3 mg · Ls mean: -7.1 · 90% CI -10.1 to -4.2
  • Group 2: Moxifloxacin 400 mg · Ls mean: 1.1 · 90% CI -2.0 to 4.2
  • Group 2: Moxifloxacin 400 mg · Ls mean: 3.1 · 90% CI -0.1 to 6.3
  • Group 2: Moxifloxacin 400 mg · Ls mean: 2.4 · 90% CI -0.1 to 4.9
  • Group 2: Moxifloxacin 400 mg · Ls mean: 3.0 · 90% CI 0.2 to 5.8
  • Group 2: Moxifloxacin 400 mg · Ls mean: 1.8 · 90% CI -1.0 to 4.6
  • Group 2: Moxifloxacin 400 mg · Ls mean: 0.6 · 90% CI -1.9 to 3.1
  • Group 2: Moxifloxacin 400 mg · Ls mean: 1.9 · 90% CI -1.0 to 4.8
  • Group 2: Moxifloxacin 400 mg · Ls mean: -0.3 · 90% CI -3.5 to 3.0
  • Group 2: Moxifloxacin 400 mg · Ls mean: 0.3 · 90% CI -2.6 to 3.2
  • Group 2: Moxifloxacin 400 mg · Ls mean: -1.9 · 90% CI -4.8 to 1.1
  • Group 2: Moxifloxacin 400 mg · Ls mean: -1.1 · 90% CI -3.8 to 1.7
  • Group 2: Moxifloxacin 400 mg · Ls mean: -0.5 · 90% CI -3.6 to 2.6
  • Group 2: Moxifloxacin 400 mg · Ls mean: -2.7 · 90% CI -5.6 to 0.2
  • Group 2: Moxifloxacin 400 mg · Ls mean: -3.5 · 90% CI -6.8 to -0.2
  • Group 2: Moxifloxacin 400 mg · Ls mean: -3.3 · 90% CI -6.6 to 0.1
  • Group 2: Moxifloxacin 400 mg · Ls mean: 0.3 · 90% CI -3.0 to 3.6
  • Group 2: Moxifloxacin 400 mg · Ls mean: -0.1 · 90% CI -3.0 to 2.9
SecondaryPlacebo-corrected CHFB in PR Intervals After Administration of SC Setmelanotide or Oral Moxifloxacin at Day 16

The CHFB in PR was analysed using an ANOVA including treatment, time and their interaction as main factors and structuring the residual matrix in order to account for the repeated measurement pattern of the data. HR was considered as covariate.

Time frame:
Baseline and Day 16: Pre dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10,12, 16, 24 hrs postdose
Reported as:
Mean · msec
Placebo-corrected CHFB in PR Intervals After Administration of SC Setmelanotide or Oral Moxifloxacin at Day 16
msecGroup 1: Setmelanotide 7 mgGroup 3: Moxifloxacin 400 mg
Pre dose-3.5 ± 7.113.4 ± 11.46
0.5 hr Post dose-4.5 ± 11.013.9 ± 9.88
1 hr Post dose0.4 ± 7.725.8 ± 10.90
1.5 hr Post dose-2.3 ± 7.452.4 ± 9.42
2 hr Post dose0.1 ± 6.672.0 ± 8.17
2.5 hr Post dose-0.9 ± 7.363.2 ± 7.46
3 hr Post dose-2.2 ± 7.122.0 ± 8.00
4 hr Post dose-1.3 ± 6.341.3 ± 9.51
5 hr Post dose-2.6 ± 6.701.2 ± 9.99
6 hr Post dose-1.7 ± 7.990.7 ± 8.87
7 hr Post dose-3.7 ± 5.65-1.1 ± 9.29
8 hr Post dose-3.1 ± 5.970.8 ± 8.52
9 hr Post dose-3.4 ± 5.080.4 ± 7.66
10 hr Post dose-1.4 ± 6.361.1 ± 7.80
12 hr Post dose-1.9 ± 5.770.8 ± 7.27
16 hr Post dose-4.9 ± 6.640.9 ± 8.78
24 hr Post dose-8.4 ± 9.212.5 ± 7.28
Statistical analysis
  • Group 1: Setmelanotide 7 mg · Ls mean: -6.6 · 90% CI -10.3 to -3.0
  • Group 1: Setmelanotide 7 mg · Ls mean: -7.3 · 90% CI -10.5 to -4.0
  • Group 1: Setmelanotide 7 mg · Ls mean: -5.0 · 90% CI -8.8 to -1.2
  • Group 1: Setmelanotide 7 mg · Ls mean: -5.0 · 90% CI -8.4 to -1.6
  • Group 1: Setmelanotide 7 mg · Ls mean: -3.5 · 90% CI -6.6 to -0.3
  • Group 1: Setmelanotide 7 mg · Ls mean: -2.9 · 90% CI -6.1 to 0.3
  • Group 1: Setmelanotide 7 mg · Ls mean: -4.6 · 90% CI -7.7 to -1.5
  • Group 1: Setmelanotide 7 mg · Ls mean: -7.1 · 90% CI -10.3 to -3.8
  • Group 1: Setmelanotide 7 mg · Ls mean: -3.2 · 90% CI -6.9 to 0.6
  • Group 1: Setmelanotide 7 mg · Ls mean: -4.2 · 90% CI -7.8 to -0.6
  • Group 1: Setmelanotide 7 mg · Ls mean: -4.8 · 90% CI -8.1 to -1.6
  • Group 1: Setmelanotide 7 mg · Ls mean: -4.4 · 90% CI -7.8 to -1.1
  • Group 1: Setmelanotide 7 mg · Ls mean: -5.9 · 90% CI -9.3 to -2.6
  • Group 1: Setmelanotide 7 mg · Ls mean: -4.4 · 90% CI -7.8 to -1.1
  • Group 1: Setmelanotide 7 mg · Ls mean: -4.2 · 90% CI -7.3 to -1.1
  • Group 1: Setmelanotide 7 mg · Ls mean: -5.8 · 90% CI -9.7 to -2.0
  • Group 1: Setmelanotide 7 mg · Ls mean: -8.2 · 90% CI -12.5 to -3.8
  • Group 3: Moxifloxacin 400 mg · Ls mean: 2.4 · 90% CI -1.2 to 5.9
  • Group 3: Moxifloxacin 400 mg · Ls mean: -1.4 · 90% CI -4.5 to 1.8
  • Group 3: Moxifloxacin 400 mg · Ls mean: -0.4 · 90% CI -4.0 to 3.3
  • Group 3: Moxifloxacin 400 mg · Ls mean: 0.3 · 90% CI -3.0 to 3.6
  • Group 3: Moxifloxacin 400 mg · Ls mean: -1.0 · 90% CI -4.0 to 2.0
  • Group 3: Moxifloxacin 400 mg · Ls mean: 0.5 · 90% CI -2.6 to 3.6
  • Group 3: Moxifloxacin 400 mg · Ls mean: -0.7 · 90% CI -3.7 to 2.3
  • Group 3: Moxifloxacin 400 mg · Ls mean: -2.3 · 90% CI -5.4 to 0.9
  • Group 3: Moxifloxacin 400 mg · Ls mean: 1.1 · 90% CI -2.5 to 4.6
  • Group 3: Moxifloxacin 400 mg · Ls mean: -0.7 · 90% CI -4.1 to 2.8
  • Group 3: Moxifloxacin 400 mg · Ls mean: -1.9 · 90% CI -5.0 to 1.3
  • Group 3: Moxifloxacin 400 mg · Ls mean: -0.5 · 90% CI -3.7 to 2.8
  • Group 3: Moxifloxacin 400 mg · Ls mean: -0.1 · 90% CI -3.4 to 3.1
  • Group 3: Moxifloxacin 400 mg · Ls mean: 0.4 · 90% CI -2.8 to 3.7
  • Group 3: Moxifloxacin 400 mg · Ls mean: 0.1 · 90% CI -2.9 to 3.1
  • Group 3: Moxifloxacin 400 mg · Ls mean: 0.6 · 90% CI -3.1 to 4.3
  • Group 3: Moxifloxacin 400 mg · Ls mean: 1.7 · 90% CI -2.5 to 5.9
SecondaryPlacebo-corrected CHFB in QRS Intervals After Administration of SC Setmelanotide or Oral Moxifloxacin at Day 10

The CHFB in QRS was analysed using an ANOVA including treatment, time and their interaction as main factors and structuring the residual matrix in order to account for the repeated measurement pattern of the data. HR was considered as covariate.

Time frame:
Baseline and Day 10: Pre dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10,12, 16, 24 hrs postdose
Reported as:
Mean · msec
Placebo-corrected CHFB in QRS Intervals After Administration of SC Setmelanotide or Oral Moxifloxacin at Day 10
msecGroup 1: Setmelanotide 3 mgGroup 2: Moxifloxacin 400 mg
Pre dose-0.2 ± 4.900.9 ± 3.42
0.5 hr Post dose0.0 ± 3.850.6 ± 6.31
1 hr Post dose0.5 ± 5.210.8 ± 3.38
1.5 hr Post dose-0.6 ± 3.69-0.2 ± 3.06
2 hr Post dose0.2 ± 4.040.1 ± 3.37
2.5 hr Post dose0.2 ± 4.410.5 ± 4.70
3 hr Post dose0.7 ± 4.310.4 ± 3.60
4 hr Post dose0.6 ± 3.95-0.7 ± 3.94
5 hr Post dose0.5 ± 3.821.0 ± 3.88
6 hr Post dose0.4 ± 4.71-0.4 ± 3.92
7 hr Post dose0.9 ± 5.300.1 ± 3.66
8 hr Post dose0.2 ± 4.231.1 ± 3.85
9 hr Post dose-0.2 ± 4.19-0.1 ± 2.93
10 hr Post dose1.6 ± 4.230.2 ± 3.95
12 hr Post dose0.8 ± 5.081.9 ± 4.10
16 hr Post dose1.0 ± 4.771.5 ± 3.97
24 hr Post dose-0.3 ± 5.381.6 ± 4.53
Statistical analysis
  • Group 1: Setmelanotide 3 mg · Ls mean: -0.7 · 90% CI -2.6 to 1.2
  • Group 1: Setmelanotide 3 mg · Ls mean: -0.9 · 90% CI -2.6 to 0.7
  • Group 1: Setmelanotide 3 mg · Ls mean: 0.6 · 90% CI -1.1 to 2.3
  • Group 1: Setmelanotide 3 mg · Ls mean: -0.1 · 90% CI -1.5 to 1.3
  • Group 1: Setmelanotide 3 mg · Ls mean: 0.8 · 90% CI -0.8 to 2.4
  • Group 1: Setmelanotide 3 mg · Ls mean: 0.7 · 90% CI -1.0 to 2.4
  • Group 1: Setmelanotide 3 mg · Ls mean: 0.2 · 90% CI -1.6 to 2.0
  • Group 1: Setmelanotide 3 mg · Ls mean: 0.7 · 90% CI -0.9 to 2.3
  • Group 1: Setmelanotide 3 mg · Ls mean: 0.5 · 90% CI -1.2 to 2.1
  • Group 1: Setmelanotide 3 mg · Ls mean: 0.9 · 90% CI -0.7 to 2.4
  • Group 1: Setmelanotide 3 mg · Ls mean: 0.9 · 90% CI -0.6 to 2.4
  • Group 1: Setmelanotide 3 mg · Ls mean: 0.6 · 90% CI -1.0 to 2.2
  • Group 1: Setmelanotide 3 mg · Ls mean: -0.2 · 90% CI -1.6 to 1.3
  • Group 1: Setmelanotide 3 mg · Ls mean: 0.0 · 90% CI -1.5 to 1.6
  • Group 1: Setmelanotide 3 mg · Ls mean: 1.4 · 90% CI -0.2 to 3.0
  • Group 1: Setmelanotide 3 mg · Ls mean: 1.5 · 90% CI -0.3 to 3.4
  • Group 1: Setmelanotide 3 mg · Ls mean: -0.2 · 90% CI -2.1 to 1.6
  • Group 2: Moxifloxacin 400 mg · Ls mean: 0.7 · 90% CI -1.2 to 2.6
  • Group 2: Moxifloxacin 400 mg · Ls mean: -0.3 · 90% CI -1.9 to 1.4
  • Group 2: Moxifloxacin 400 mg · Ls mean: 0.5 · 90% CI -1.2 to 2.2
  • Group 2: Moxifloxacin 400 mg · Ls mean: 0.7 · 90% CI -0.7 to 2.1
  • Group 2: Moxifloxacin 400 mg · Ls mean: 0.6 · 90% CI -1.1 to 2.2
  • Group 2: Moxifloxacin 400 mg · Ls mean: 0.8 · 90% CI -0.9 to 2.5
  • Group 2: Moxifloxacin 400 mg · Ls mean: 0.3 · 90% CI -1.5 to 2.1
  • Group 2: Moxifloxacin 400 mg · Ls mean: -0.5 · 90% CI -2.1 to 1.1
  • Group 2: Moxifloxacin 400 mg · Ls mean: 0.2 · 90% CI -1.5 to 1.9
  • Group 2: Moxifloxacin 400 mg · Ls mean: -0.2 · 90% CI -1.7 to 1.4
  • Group 2: Moxifloxacin 400 mg · Ls mean: -0.1 · 90% CI -1.6 to 1.4
  • Group 2: Moxifloxacin 400 mg · Ls mean: 0.8 · 90% CI -0.7 to 2.4
  • Group 2: Moxifloxacin 400 mg · Ls mean: -0.2 · 90% CI -1.6 to 1.3
  • Group 2: Moxifloxacin 400 mg · Ls mean: 0.1 · 90% CI -1.4 to 1.6
  • Group 2: Moxifloxacin 400 mg · Ls mean: 1.5 · 90% CI -0.1 to 3.1
  • Group 2: Moxifloxacin 400 mg · Ls mean: 1.2 · 90% CI -0.7 to 3.0
  • Group 2: Moxifloxacin 400 mg · Ls mean: 1.5 · 90% CI -0.3 to 3.4
SecondaryPlacebo-corrected CHFB in QRS Intervals After Administration of SC Setmelanotide or Oral Moxifloxacin at Day 16

The CHFB in QRS was analyzed using an ANOVA including treatment, time and their interaction as main factors and structuring the residual matrix in order to account for the repeated measurement pattern of the data. HR was considered as covariate.

Time frame:
Baseline and Day 16: Pre dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10,12, 16, 24 hrs postdose
Reported as:
Mean · msec
Placebo-corrected CHFB in QRS Intervals After Administration of SC Setmelanotide or Oral Moxifloxacin at Day 16
msecGroup 1: Setmelanotide 7 mgGroup 3: Moxifloxacin 400 mg
Pre dose1.0 ± 4.11-0.8 ± 3.90
0.5 hr Post dose0.5 ± 3.570.2 ± 3.90
1 hr Post dose0.9 ± 3.20-1.0 ± 6.86
1.5 hr Post dose-0.8 ± 3.06-0.4 ± 3.65
2 hr Post dose-0.2 ± 3.970.3 ± 3.41
2.5 hr Post dose1.1 ± 2.95-0.2 ± 4.20
3 hr Post dose0.5 ± 2.911.0 ± 3.69
4 hr Post dose0.7 ± 4.350.5 ± 2.93
5 hr Post dose-0.2 ± 4.31-1.4 ± 5.54
6 hr Post dose-0.2 ± 4.630.3 ± 2.99
7 hr Post dose1.5 ± 4.920.7 ± 4.10
8 hr Post dose-0.2 ± 4.030.7 ± 2.77
9 hr Post dose0.2 ± 4.13-0.4 ± 3.15
10 hr Post dose1.2 ± 3.19-1.2 ± 2.73
12 hr Post dose1.4 ± 5.13-0.2 ± 4.74
16 hr Post dose1.1 ± 2.90-0.7 ± 4.75
24 hr Post dose1.3 ± 4.680.5 ± 3.69
Statistical analysis
  • Group 1: Setmelanotide 7 mg · Ls mean: 0.8 · 90% CI -1.3 to 2.9
  • Group 1: Setmelanotide 7 mg · Ls mean: -0.3 · 90% CI -1.8 to 1.2
  • Group 1: Setmelanotide 7 mg · Ls mean: 1.2 · 90% CI -1.4 to 3.8
  • Group 1: Setmelanotide 7 mg · Ls mean: -0.0 · 90% CI -1.8 to 1.8
  • Group 1: Setmelanotide 7 mg · Ls mean: -1.4 · 90% CI -3.0 to 0.3
  • Group 1: Setmelanotide 7 mg · Ls mean: 1.6 · 90% CI -0.0 to 3.1
  • Group 1: Setmelanotide 7 mg · Ls mean: -0.1 · 90% CI -1.7 to 1.5
  • Group 1: Setmelanotide 7 mg · Ls mean: 1.3 · 90% CI -0.3 to 2.9
  • Group 1: Setmelanotide 7 mg · Ls mean: -0.1 · 90% CI -2.2 to 2.0
  • Group 1: Setmelanotide 7 mg · Ls mean: 0.7 · 90% CI -0.8 to 2.3
  • Group 1: Setmelanotide 7 mg · Ls mean: 0.9 · 90% CI -0.8 to 2.7
  • Group 1: Setmelanotide 7 mg · Ls mean: 1.0 · 90% CI -0.3 to 2.4
  • Group 1: Setmelanotide 7 mg · Ls mean: 1.1 · 90% CI -0.7 to 2.9
  • Group 1: Setmelanotide 7 mg · Ls mean: 0.3 · 90% CI -1.4 to 1.9
  • Group 1: Setmelanotide 7 mg · Ls mean: 1.3 · 90% CI -0.6 to 3.2
  • Group 1: Setmelanotide 7 mg · Ls mean: 0.7 · 90% CI -1.0 to 2.4
  • Group 1: Setmelanotide 7 mg · Ls mean: 1.6 · 90% CI -1.0 to 4.2
  • Group 3: Moxifloxacin 400 mg · Ls mean: -0.3 · 90% CI -2.3 to 1.7
  • Group 3: Moxifloxacin 400 mg · Ls mean: -0.1 · 90% CI -1.6 to 1.3
  • Group 3: Moxifloxacin 400 mg · Ls mean: -1.3 · 90% CI -3.8 to 1.2
  • Group 1: Setmelanotide 7 mg · Ls mean: 0.1 · 90% CI -1.7 to 1.8
  • Group 3: Moxifloxacin 400 mg · Ls mean: -1.1 · 90% CI -2.7 to 0.5
  • Group 3: Moxifloxacin 400 mg · Ls mean: 0.7 · 90% CI -0.8 to 2.3
  • Group 3: Moxifloxacin 400 mg · Ls mean: 0.2 · 90% CI -1.3 to 1.8
  • Group 3: Moxifloxacin 400 mg · Ls mean: 0.3 · 90% CI -1.2 to 1.9
  • Group 1: Setmelanotide 7 mg · Ls mean: -1.5 · 90% CI -3.5 to 0.5
  • Group 3: Moxifloxacin 400 mg · Ls mean: 0.9 · 90% CI -0.6 to 2.3
  • Group 3: Moxifloxacin 400 mg · Ls mean: 0.4 · 90% CI -1.3 to 2.1
  • Group 3: Moxifloxacin 400 mg · Ls mean: 1.3 · 90% CI -0.0 to 2.6
  • Group 3: Moxifloxacin 400 mg · Ls mean: 0.4 · 90% CI -1.3 to 2.2
  • Group 3: Moxifloxacin 400 mg · Ls mean: -1.1 · 90% CI -2.7 to 0.5
  • Group 3: Moxifloxacin 400 mg · Ls mean: -0.3 · 90% CI -2.1 to 1.5
  • Group 3: Moxifloxacin 400 mg · Ls mean: -0.2 · 90% CI -1.9 to 1.4
  • Group 3: Moxifloxacin 400 mg · Ls mean: 2.3 · 90% CI -0.2 to 4.9
SecondaryNumber of Participants With at Least One Treatment-Emergent Abnormal Value in HR Intervals After Administration of SC Setmelanotide

A treatment-emergent abnormality/finding was defined as any abnormality/finding not already reported on any of the ECGs collected before the administration. Abnormal findings included: HR (\<40 beats/min, HR\>120 beats/min and Relative CHFB \>25%) Relative CHFB = 100\*(Value-Baseline)/Baseline

Time frame:
Day 10 (for setmelanotide 3 mg) and Day 16 (for setmelanotide 7mg)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Treatment-Emergent Abnormal Value in HR Intervals After Administration of SC Setmelanotide
ParticipantsGroup 1: Setmelanotide 3 mgGroup 1: Setmelanotide 7 mg
HR<40 beats/min00
HR>120 beats/min00
Relative CHFB in HR>25%49
SecondaryNumber of Participants With at Least One Treatment-Emergent Abnormal Value in PR Intervals After Administration of SC Setmelanotide

A treatment-emergent abnormality/finding was defined as any abnormality/finding not already reported on any of the ECGs collected before the administration. Abnormal findings included: PR (\>220 msec, Relative CHFB \>25%); Relative CHFB = 100\*(Value-Baseline)/Baseline

Time frame:
Day 10 (for setmelanotide 3 mg) and Day 16 (for setmelanotide 7mg)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Treatment-Emergent Abnormal Value in PR Intervals After Administration of SC Setmelanotide
ParticipantsGroup 1: Setmelanotide 3 mgGroup 1: Setmelanotide 7 mg
PR>220 msec00
Relative CHFB in PR>25%00
SecondaryNumber of Participants With at Least One Treatment-Emergent Abnormal Value in QRS Intervals After Administration of SC Setmelanotide

A treatment-emergent abnormality/finding was defined as any abnormality/finding not already reported on any of the ECGs collected before the administration. Abnormal findings included: QRS ( \>120 msec, Relative CHFB \>25%); Relative CHFB = 100\*(Value-Baseline)/Baseline

Time frame:
Day 10 (for setmelanotide 3 mg) and Day 16 (for setmelanotide 7mg)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Treatment-Emergent Abnormal Value in QRS Intervals After Administration of SC Setmelanotide
ParticipantsGroup 1: Setmelanotide 3 mgGroup 1: Setmelanotide 7 mg
QRS>120 msec00
Relative CHFB in QRS>25%00
SecondaryNumber of Participants With at Least One Treatment-Emergent Abnormal Value in QTcF Intervals After Administration of SC Setmelanotide

A treatment-emergent abnormality/finding was defined as any abnormality/finding not already reported on any of the ECGs collected before the administration. Abnormal findings included: QTcF (450\<QTc\<=480 msec, 480\<QTc\<=500 msec, QTc\>500 msec, 30\<CHFB in QTc\<=60 msec, CHFB in \>60 msec)

Time frame:
Day 10 (for setmelanotide 3 mg) and Day 16 (for setmelanotide 7mg)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Treatment-Emergent Abnormal Value in QTcF Intervals After Administration of SC Setmelanotide
ParticipantsGroup 1: Setmelanotide 3 mgGroup 1: Setmelanotide 7 mg
450<QTc<=480 msec00
480<QTc<=500 msec00
QTc>500 msec00
30<CHFB in QTc<=60 msec00
CHFB in QTc>60 msec00
SecondaryNumber of Participants With at Least One Treatment-Emergent Abnormal Finding in T-wave Morphology and U-wave Presence After Administration of SC Setmelanotide

A treatment-emergent abnormality/finding will be defined as any abnormality/finding not already reported on any of the ECGs collected before the administration. Abnormal findings included : QTcF Increase From Baseline, \> 30 msec And \< 60 msec

Time frame:
Day 10 (for setmelanotide 3 mg) and Day 16 (for setmelanotide 7mg)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Treatment-Emergent Abnormal Finding in T-wave Morphology and U-wave Presence After Administration of SC Setmelanotide
ParticipantsGroup 1: Setmelanotide 3 mgGroup 1: Setmelanotide 7 mg
Number of Participants With at Least One Treatment-Emergent Abnormal Finding in T-wave Morphology and U-wave Presence After Administration of SC Setmelanotide11
SecondaryMoxifloxacin Concentration-related CHFB in QTcF at Day 10

Continuous 12-lead digital ECG recording was performed on Baseline and Day 10. ECG analysts were blinded to the treatment, timepoint and participant. CHFB in QTcF was calculated at each timepoint.

Time frame:
Baseline and Day 10: Pre dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10,12, 16, 24 hrs postdose
Reported as:
Mean · msec
Moxifloxacin Concentration-related CHFB in QTcF at Day 10
msecGroup 2: Moxifloxacin 400 mg
Pre dose1.5 ± 7.76
0.5 hr Post dose-5.3 ± 8.75
1 hr Post dose-3.7 ± 9.39
1.5 hr Post dose0.9 ± 8.56
2 hr Post dose2.0 ± 8.74
2.5 hr Post dose4.9 ± 8.75
3 hr Post dose4.9 ± 7.39
4 hr Post dose6.3 ± 8.63
5 hr Post dose8.1 ± 8.42
6 hr Post dose6.0 ± 6.61
7 hr Post dose5.1 ± 8.39
8 hr Post dose4.4 ± 8.18
9 hr Post dose5.0 ± 10.47
10 hr Post dose6.2 ± 6.85
12 hr Post dose8.7 ± 4.84
16 hr Post dose5.9 ± 8.09
24 hr Post dose6.6 ± 8.00
SecondaryMoxifloxacin Concentration-related CHFB in QTcF at Day 16

Continuous 12-lead digital ECG recording was performed on Baseline and Day 16. ECG analysts were blinded to the treatment, timepoint and participant. CHFB in QTcF was calculated at each timepoint.

Time frame:
Baseline and Day 16: Pre dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10,12, 16, 24 hrs postdose
Reported as:
Mean · msec
Moxifloxacin Concentration-related CHFB in QTcF at Day 16
msecGroup 3: Moxifloxacin 400 mg
Pre dose-0.8 ± 8.30
0.5 hr Post dose-1.8 ± 5.93
1 hr Post dose-1.9 ± 7.49
1.5 hr Post dose3.0 ± 7.05
2 hr Post dose4.2 ± 7.53
2.5 hr Post dose7.6 ± 8.45
3 hr Post dose8.1 ± 8.19
4 hr Post dose8.8 ± 6.37
5 hr Post dose7.5 ± 8.97
6 hr Post dose8.5 ± 6.18
7 hr Post dose9.1 ± 7.29
8 hr Post dose8.0 ± 5.73
9 hr Post dose7.0 ± 7.33
10 hr Post dose7.0 ± 9.93
12 hr Post dose10.8 ± 9.14
16 hr Post dose6.6 ± 8.51
24 hr Post dose4.4 ± 10.57

Adverse events

Collected over From first dose up to Day 23. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: Setmelanotide 2 mg0/28 (0%)1/28 (3.6%)25/28 (89.3%)
Group 1: Setmelanotide 3 mg0/24 (0%)0/24 (0%)16/24 (66.7%)
Group 1: Setmelanotide 5 mg0/23 (0%)0/23 (0%)17/23 (73.9%)
Group 1: Setmelanotide 7 mg0/21 (0%)0/21 (0%)9/21 (42.9%)
Group 2: Placebo0/24 (0%)0/24 (0%)18/24 (75%)
Group 2: Moxifloxacin 400mg0/23 (0%)0/23 (0%)17/23 (73.9%)
Group 3: Placebo0/25 (0%)0/25 (0%)15/25 (60%)
Group 3: Moxifloxacin 400mg0/25 (0%)0/25 (0%)4/25 (16%)
Most frequent serious events
Most frequent serious events
EventGroup 1: Setmelanotide 2 mgGroup 1: Setmelanotide 3 mgGroup 1: Setmelanotide 5 mgGroup 1: Setmelanotide 7 mgGroup 2: PlaceboGroup 2: Moxifloxacin 400mgGroup 3: PlaceboGroup 3: Moxifloxacin 400mg
Pancreatitis acuteGastrointestinal disorders1/280/240/230/210/240/230/250/25
Hepatitis acuteHepatobiliary disorders1/280/240/230/210/240/230/250/25
Most frequent other events
Showing 10 of 63
Most frequent other events
EventGroup 1: Setmelanotide 2 mgGroup 1: Setmelanotide 3 mgGroup 1: Setmelanotide 5 mgGroup 1: Setmelanotide 7 mgGroup 2: PlaceboGroup 2: Moxifloxacin 400mgGroup 3: PlaceboGroup 3: Moxifloxacin 400mg
Injection site painGeneral disorders11/287/246/237/218/2412/2311/250/25
NauseaGastrointestinal disorders13/280/244/232/211/240/230/252/25
Injection site erythemaGeneral disorders7/2810/247/232/211/246/236/250/25
Injection site swellingGeneral disorders4/281/243/234/211/244/239/250/25
VomitingGastrointestinal disorders8/280/241/231/211/240/230/250/25
EphelidesSkin and subcutaneous tissue disorders6/281/240/230/210/240/231/250/25
Decreased appetiteMetabolism and nutrition disorders6/280/242/230/210/240/230/250/25
Skin hyperpigmentationSkin and subcutaneous tissue disorders5/282/240/231/212/240/230/250/25
Injection site pruritusGeneral disorders3/284/243/231/213/241/234/250/25
HeadacheNervous system disorders4/280/241/231/212/240/231/250/25

Baseline characteristics

The Safety population included all participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Group 1: Setmelanotide 2-7 mg + Placebo for MoxifloxacinGroup 2: Placebo for Setmelanotide + Moxifloxacin 400 mg + Placebo for MoxifloxacinGroup 3: Placebo for Setmelanotide + Placebo for Moxifloxacin + Moxifloxacin 400 mgTotal
Mean31.9 ± 6.4736.1 ± 9.2834.8 ± 8.6034.2 ± 8.22
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: Setmelanotide 2-7 mg + Placebo for MoxifloxacinGroup 2: Placebo for Setmelanotide + Moxifloxacin 400 mg + Placebo for MoxifloxacinGroup 3: Placebo for Setmelanotide + Placebo for Moxifloxacin + Moxifloxacin 400 mgTotal
Female10111233
Male18131344
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group 1: Setmelanotide 2-7 mg + Placebo for MoxifloxacinGroup 2: Placebo for Setmelanotide + Moxifloxacin 400 mg + Placebo for MoxifloxacinGroup 3: Placebo for Setmelanotide + Placebo for Moxifloxacin + Moxifloxacin 400 mgTotal
Hispanic or Latino791026
Not Hispanic or Latino21151551
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group 1: Setmelanotide 2-7 mg + Placebo for MoxifloxacinGroup 2: Placebo for Setmelanotide + Moxifloxacin 400 mg + Placebo for MoxifloxacinGroup 3: Placebo for Setmelanotide + Placebo for Moxifloxacin + Moxifloxacin 400 mgTotal
American Indian or Alaska Native0000
Asian1326
Native Hawaiian or Other Pacific Islander0000
Black or African American105823
White13131238
More than one race0000
Unknown or Not Reported43310
08

Study locations

1 site
  • Parexel Early Phase Clinical Unit (Los Angeles)
    Glendale, California 91206, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2021 to primary completion in Apr 2022, 8 months.

Results were first posted in May 2024, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2021
First posted
Sep 16, 2021
StartActual
Aug 5, 2021
Primary completionActual
Apr 7, 2022
CompletionActual
Apr 7, 2022
Results first posted
May 3, 2024
Last update
May 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05046132
Responsible party
Sponsor
First posted
Sep 16, 2021
Start date
Aug 5, 2021
Primary completion
Apr 7, 2022
Completion
Apr 7, 2022
Results posted
May 3, 2024
Last update
May 3, 2024

Study contacts

David Meeker, MD
study chair · Rhythm Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Setmelanotide

Start the discussion